Search

Nordic Pharma Announces CE Mark Approval for Lacrifill® Canalicular Gel, Paving the Way for European Launch

Nordic group B.V – an international pharmaceutical company operating as Nordic Pharma have received CE mark approval for Lacrifill®, a novel dry eye therapy. Lacrifill® is a cross-linked hyaluronic acid gel that temporarily blocks tear drainage by occluding the canalicular...

Heidelberg Engineering announces partnership with Hospital Services Ltd for distribution and service in Ireland

Heidelberg Engineering is excited to announce a strategic partnership with Hospital Services Ltd (HSL), which will take over as the exclusive distributor and service provider of the Heidelberg Engineering range of products in the Republic of Ireland, effective 1st July...

New Online Ophthalmology Portfolio Points Calculator

Applying for Ophthalmology ST1 is a competitive and often stressful process, with many applicants finding the portfolio self-assessment scoring system difficult to navigate. To make this process easier, a new online tool - MedPoints - has been developed to give...

Sight Sciences at ESCRS

The Sight Sciences team recently returned from an incredibly busy and successful ESCRS congress in Copenhagen. The team were in town to support the MIGS masterclass programme and were pleased to spend time with customers, colleagues and contacts from across...

Eye Juniors Introduction to the ST1 Application 2025-26

Join Eye Juniors for their Introduction to ST1 Ophthalmology Application 2025-2026. In this free talk high scoring trainees will talk you through the entire ST1 application process – from the MSRA and portfolio to the interview. They’ve been running the...

From Dye to Digital: Why OCTA is replacing invasive imaging in retinal care

For decades, retinal imaging has relied on invasive dye based techniques to visualise the eye’s vasculature. However, Optical Coherence Tomography Angiography (OCTA) is fast becoming the preferred modality, replacing fluorescein and ICG angiography in many clinical settings. As highlighted by...

Andrew Geddes Becomes Vice President and Head of European Operations at Glaukos

Glaukos announces that Andrew Geddes is to become Vice President and Head of European Operations, recognising his eight years of leadership and contributions to the company’s growth. In this role, Geddes will lead Glaukos’ strategic expansion in Europe, Middle East...

Global Experts Unite: Visionary Horizons Sets the Stage for the Future of Ophthalmology

Heidelberg Engineering, as part of EssilorLuxottica, marked a milestone in global eyecare innovation with the inaugural Visionary Horizons symposium — the first event of its kind showcasing Heidelberg’s pioneering innovation and expertise as a driving force within EssilorLuxottica’s technological and...

Birmingham Optical welcomes Irem Ali as Chief Commercial Officer

She brings with her extensive experience across sales, marketing, and operations within the MedTech, healthcare, and pharmaceutical sectors. Commenting on her appointment, Irem said: “I am delighted to be joining a growing organisation at such a pivotal time. The team...

Oertli launches OS 4 Up™ in CE-certified markets

Oertli Instrumente AG announces the commercial launch of its new surgical platform, OS 4 Up™, for cataract and vitreoretinal surgery. Development, design and production are carried out entirely at the company's headquarters in Berneck, Switzerland. The family-run company is thus...

Glaukos marks major milestone as global iStent sales reach 3 million

Glaukos is delighted to announce a major milestone revealing that 3 million iStents have been sold globally since the product first received approval from the FDA in 2012. Today iStent is the global market leader in the MIGs category with...

Altomed at EyeConUK 2026

Altomed are pleased to confirm they will be attending RCOphth congress in May with their ever-popular hands-on workstations and practice lab. Once again, we will have the much talked about Malyugin Ring #fastestestringer challenge, SimulEYE training models and try before...